Haemacure gets Swiss ZLB fibrinogen approval:
This article was originally published in Clinica
Executive Summary
The Swiss ZLB national blood transfusion service has confirmed that it will be spending SwFr21 million ($14 million) in constructing a production plant for the protein components of Haemocure's Hemaseel HMN. The product is designed to arrest bleeding and seal wounds. ZLB gained a co-operation and licensing agreement last year, giving it worldwide rights to produce fibrinogen and thrombin. Haemacure keeps the rights to market all products under the agreement.